487 related articles for article (PubMed ID: 23575412)
1. Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906L.
Kogure Y; Ando M; Saka H; Chiba Y; Yamamoto N; Asami K; Hirashima T; Seto T; Nagase S; Otsuka K; Yanagihara K; Takeda K; Okamoto I; Aoki T; Takayama K; Yamasaki M; Kudoh S; Katakami N; Miyazaki M; Nakagawa K
J Thorac Oncol; 2013 Jun; 8(6):753-8. PubMed ID: 23575412
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.
Paz-Ares L; Bálint B; de Boer RH; van Meerbeeck JP; Wierzbicki R; De Souza P; Galimi F; Haddad V; Sabin T; Hei YJ; Pan Y; Cottrell S; Hsu CP; RamLau R
J Thorac Oncol; 2013 Mar; 8(3):329-37. PubMed ID: 23370314
[TBL] [Abstract][Full Text] [Related]
3. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC.
Kawaguchi T; Takada M; Kubo A; Matsumura A; Fukai S; Tamura A; Saito R; Maruyama Y; Kawahara M; Ignatius Ou SH
J Thorac Oncol; 2010 May; 5(5):620-30. PubMed ID: 20354456
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer.
Besse B; Planchard D; Veillard AS; Taillade L; Khayat D; Ducourtieux M; Pignon JP; Lumbroso J; Lafontaine C; Mathiot C; Soria JC
Lung Cancer; 2012 Apr; 76(1):78-83. PubMed ID: 22186627
[TBL] [Abstract][Full Text] [Related]
6. Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors.
Chen KY; Chen JH; Shih JY; Yang CH; Yu CJ; Yang PC
J Thorac Oncol; 2010 Jan; 5(1):82-9. PubMed ID: 19884854
[TBL] [Abstract][Full Text] [Related]
7. Serpin b3 is associated with poor survival after chemotherapy and is a potential novel predictive biomarker in advanced non-small-cell lung cancer.
Urquhart G; Kerr KM; Nicolson M; Loo PS; Sharma R; Shrimali R; Petty RD
J Thorac Oncol; 2013 Dec; 8(12):1502-9. PubMed ID: 24389432
[TBL] [Abstract][Full Text] [Related]
8. Lung cancer in women, a different disease: survival differences by sex in Turkey.
Ulas A; Tokluoglu S; Kos M; Silay K; Akinci S; Oksuzoglu B; Alkis N
Asian Pac J Cancer Prev; 2015; 16(2):815-22. PubMed ID: 25684531
[TBL] [Abstract][Full Text] [Related]
9. First-line gefitinib treatment for patients with advanced non-small cell lung cancer with poor performance status.
Lee YJ; Kim HT; Han JY; Yun T; Lee GK; Kim HY; Sung JH; Lee JS
J Thorac Oncol; 2010 Mar; 5(3):361-8. PubMed ID: 20107420
[TBL] [Abstract][Full Text] [Related]
10. Improvement in population-based survival of stage IV NSCLC due to increased use of chemotherapy.
Aarts MJ; van den Borne BE; Biesma B; Kloover JS; Aerts JG; Lemmens VE
Int J Cancer; 2015 Mar; 136(5):E387-95. PubMed ID: 25219898
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of ratio-based lymph node staging in resected non-small-cell lung cancer.
Qiu C; Dong W; Su B; Liu Q; Du J
J Thorac Oncol; 2013 Apr; 8(4):429-35. PubMed ID: 23486264
[TBL] [Abstract][Full Text] [Related]
12. Survival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib: expanded access programme data from Belgium (the TRUST study).
Van Meerbeeck J; Galdermans D; Bustin F; De Vos L; Lechat I; Abraham I
Eur J Cancer Care (Engl); 2014 May; 23(3):370-9. PubMed ID: 24152297
[TBL] [Abstract][Full Text] [Related]
13. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
Scagliotti GV; De Marinis F; Rinaldi M; Crinò L; Gridelli C; Ricci S; Zhao YD; Liepa AM; Peterson P; Tonato M
J Thorac Oncol; 2009 Dec; 4(12):1568-71. PubMed ID: 20009911
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of number of resected and involved lymph nodes at complete resection on survival in non-small cell lung cancer.
Saji H; Tsuboi M; Yoshida K; Kato Y; Nomura M; Matsubayashi J; Nagao T; Kakihana M; Usuda J; Kajiwara N; Ohira T; Ikeda N
J Thorac Oncol; 2011 Nov; 6(11):1865-71. PubMed ID: 21964529
[TBL] [Abstract][Full Text] [Related]
16. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
17. Outcome of treated advanced non-small cell lung cancer with and without central airway obstruction.
Chhajed PN; Baty F; Pless M; Somandin S; Tamm M; Brutsche MH
Chest; 2006 Dec; 130(6):1803-7. PubMed ID: 17167000
[TBL] [Abstract][Full Text] [Related]
18. Retrospective analysis of third-line chemotherapy in advanced non-small cell lung cancer.
Tatli AM; Arslan D; Uysal M; Goksu SS; Gunduz SG; Coskun HS; Ozdogan M; Savas B; Bozcuk HS
J Cancer Res Ther; 2015; 11(4):805-9. PubMed ID: 26881522
[TBL] [Abstract][Full Text] [Related]
19. Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.
Asahina H; Sekine I; Horinouchi H; Nokihara H; Yamamoto N; Kubota K; Tamura T
Clin Lung Cancer; 2012 Jan; 13(1):39-43. PubMed ID: 21890422
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer.
Rodrigues-Pereira J; Kim JH; Magallanes M; Lee DH; Wang J; Ganju V; Martínez-Barrera L; Barraclough H; van Kooten M; Orlando M
J Thorac Oncol; 2011 Nov; 6(11):1907-14. PubMed ID: 22005471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
